TITLE

European pharma consolidation generates quality spinoffs

AUTHOR(S)
Sheridan, Cormac
PUB. DATE
December 2006
SOURCE
Nature Biotechnology;Dec2006, Vol. 24 Issue 12, p1458
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on the consolidation and acquisition of European pharmaceutical companies. The article discuses that Berlin based Schering company and two German companies are acquired by Bayer Healthcare, Germany, to establish Bayer-Schering Pharma. And the establishment will concentrate on oncology , cardiovascular disease, multiple sclerosis and women's health related medicines. The article also presents a list of companies acquired by Big Pharma.
ACCESSION #
23358451

 

Related Articles

  • Alliances & Licensing Update.  // PharmaWatch: Cancer;Aug2010, Vol. 9 Issue 8, p12 

    The article offers news briefs related to strategic alliances in pharmaceutical companies. The drug development company Aeterna Zentaris Inc. has collaborated with Almac Diagnostic to develop cancer diagnostic. Bayer Schering Pharma AG has formed a strategic alliance with OncoMed Pharmaceuticals...

  • SWOT Analysis.  // Schering AG SWOT Analysis;Jun2007, p5 

    A business analysis of Bayer Schering Pharma AG, a global pharmaceutical company that is active in areas such as gynecology, andrology, oncology, diagnostic imaging and specialized therapeutics, is provided, focusing on its strengths, weaknesses, opportunities for improvement and threats to the...

  • New step for Bayer Schering.  // R&D Magazine;Jan2007, Vol. 49 Issue 1, p12 

    The article reports that Schering has been renamed to Bayer Schering Pharma AG following its acquisition by Bayer AG in July 2006. According to Werner Wenning, Bayer AG management board chairman, the firm is focusing on the next steps. Bayer Schering Pharma AG together with Bayer's...

  • Schering renamed.  // European Pharmaceutical Executive;Feb/Mar2007, p10 

    The article reports on Germany-based Schering AG's decision to change its name to Bayer Schering Pharma AG. The necessary entry in the commercial register took effect on December 29, 2006. The article also reports that the new logo has been mounted on Bayer Schering Pharma's headquarters in...

  • TOP 20 PHARMA: #15 BAYER SCHERING.  // Contract Pharma;2009, Vol. 11 Issue 6, p84 

    The article profiles Bayer Schering Pharma AG, the rank 15 among the top 20 pharmaceutical companies based in Leverkusen, Germany. It notes that it was founded in 1971 and handles 108,600 employees. It mentions its plan to strengthen its research and development initiative in 2009 through its 4...

  • Schering and Bayer seal drug ownership agreement. Chynoweth, Emma // ICIS Chemical Business;4/2/2007, Vol. 2 Issue 60, p33 

    This article reports that Bayer Schering Pharma and Novartis have settled a dispute over U.S. production of the interferon-based multiple sclerosis treatment Betaseron, sold in the U.S. as Betaferon. The deal sees Bayer Schering Pharma acquiring most of Novartis' Emeryville, California, site,...

  • Direvo Antibodies, Proteases Moving to Bayer Pipeline. Hollingsworth, Catherine // BioWorld Today;9/17/2008, Vol. 19 Issue 181, p1 

    The article reports on the acquisition of Direvo Biotech AG by Bayer HealthCare AG in September 2008. The €210 million deal will reportedly allow Bayer Healthcare to strengthen its biologicals research in the Bayer Schering Pharma AG division. It offers information on the protein...

  • Bayer Schering job cuts. William, Dede; Gibson, Jane // ICIS Chemical Business Americas;3/5/2007, Vol. 271 Issue 9, p13 

    This article reports that Schering is set to cut 950 jobs at its headquarters in Berlin, Germany by 2009. Werner Wenning, Bayer chairman, said the move is due to the merger between the pharmaceutical activities of Schering and Bayer. Wenning, who is also chairman of Bayer Schering Pharma's...

  • Bayer completes acquisition of U.S biologics manufacturing facility from Novartis.  // Chemical Business;Oct2007, Vol. 21 Issue 10, p75 

    The article reports on the acquisition by Bayer of a biologics manufacturing facility in California from Novartis in October 2007. Under the deal, the drug Betaseron will be manufactured by Bayer, retain all employees involved in the production of the drug. Reportedly, Novartis has also...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics